What does the evidence show about MOTS-c's effects?

Read Off Label rates the evidence for MOTS-c as Preclinical-Weak human and the benefit magnitude as variable, producing an overall grade of C+ (5.5/10). Reynolds 2020 Nature Commun: MOTS-c injection improved exercise performance in old mice to young-mouse levels.

Rankings / Longevity — Peptides

MOTS-c

Longevity · Mitochondrial-derived peptide

Tier C+

Reviewed by Read Off Label · Last reviewed Jul 27, 2026 · How we grade

ampkpeptidemitochondrialresearch-only

5.5 / 10

Tier C+

Ev 2.5 Bn 5 Sf 9

Bottom line

Read Off Label grades MOTS-c as C+ (5.5/10) based on preclinical-weak human evidence, variable benefit magnitude, and a low-risk safety profile.

Reynolds 2020 Nature Commun: MOTS-c injection improved exercise performance in old mice to young-mouse levels.

Studied, labeled, or reported-use context: 5-10 mg SC 2-3x/week in cycles — Research chemical; PCAC voted 7-5 (two abstentions) in favour of adding MOTS-c to the 503A bulks list (Jul 23-24, 2026) — advisory only, not an FDA approval or a final compounding decision; not individualized guidance.

Frontier potential — editorial judgment, not evidence

This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.

4/10

Mechanistic story only First-in-human

What the ceiling rests on

A mitochondrial-derived peptide — a genuinely novel signalling class — that improved exercise capacity in old mice to the level of young animals, and whose circulating levels rise with exercise in humans, suggesting it is part of a real physiological pathway rather than a pharmacological curiosity.

Why it may not get there

Everything above is mouse work plus a human correlation. The first registered human trial began recruiting in 2026 and has no results. Injectable, unapproved, with no established human dose, and the correlation between exercise and circulating MOTS-c does not establish that administering it reproduces the effect.

What would change this First published human trial results.

If you were testing this on yourself

Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.

Can you undo it?

Slow to reverse

No human safety data, so reversibility is unknown rather than established.

Can you tell if it worked?

Nothing you can measure

No endpoint exists that you could observe for the reason this is taken. An experiment without a readout cannot tell you anything, however it turns out.

What would fool you The first human trial is still recruiting. Exercise raises endogenous MOTS-c, so any perceived benefit in someone who is also training is unattributable.

What the evidence says

Reynolds 2020 Nature Commun: MOTS-c injection improved exercise performance in old mice to young-mouse levels. Circulating MOTS-c increases with exercise in humans. No published human RCTs for longevity endpoints. Very early stage. FDA briefing documents for the Jul 23-24, 2026 Pharmacy Compounding Advisory Committee hearing were posted ahead of the meeting: FDA's stated position is to recommend against adding this peptide to the 503A bulks list, citing poor characterization, weak human efficacy/safety evidence, and unassessed immunogenicity risk (same position taken on BPC-157, KPV, TB-500, and MOTS-c). PCAC is advisory only; no final decision yet. A Phase 2a RCT (Hudson Biotech, NCT07505745, n=120) evaluating MOTS-c in adults with prediabetes and overweight/obesity began recruiting Feb 2026 -- the first registered human trial for this peptide; no results yet. The July 23-24, 2026 PCAC hearing convened as scheduled; outcome not yet published as of this sweep. The FDA Pharmacy Compounding Advisory Committee (PCAC) met Jul 23-24, 2026 and voted on seven peptides for the 503A bulk drug substances list. Committee votes are advisory: the FDA is not bound by them, adding a substance to the 503A list would follow notice-and-comment rulemaking, and inclusion would permit compounding — it would not constitute FDA approval, an efficacy finding, or a safety determination. FDA's own review staff had recommended against the four Jul 23 peptides, citing poor characterization, weak human efficacy and safety evidence, and unassessed immunogenicity; press coverage also noted committee members' financial ties to the peptide industry. The underlying human evidence base for these compounds is unchanged by the vote. On this compound the committee voted 7-5 (two abstentions) in favour of adding MOTS-c to the 503A bulks list.

Mechanism

Peptide encoded by mitochondrial 12S rRNA; activates AMPK; enhances glucose uptake and fatty acid oxidation; nuclear translocation to regulate stress-response genes; exercise-induced

Studied, labeled, or reported dose & route

5-10 mg SC 2-3x/week in cycles

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about MOTS-c's effects?: Read Off Label rates the evidence for MOTS-c as Preclinical-Weak human and the benefit magnitude as variable, producing an overall grade of C+ (5.5/10). Reynolds 2020 Nature Commun: MOTS-c injection improved exercise performance in old mice to young-mouse levels.
What safety findings are reported for MOTS-c?: MOTS-c has a low risk profile in the database. Low (from limited data) Legal status: Research chemical; PCAC voted 7-5 (two abstentions) in favour of adding MOTS-c to the 503A bulks list (Jul 23-24, 2026) — advisory only, not an FDA approval or a final compounding decision.
What doses or routes are reported for MOTS-c?: 5-10 mg SC 2-3x/week in cycles This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does MOTS-c work?: Peptide encoded by mitochondrial 12S rRNA; activates AMPK; enhances glucose uptake and fatty acid oxidation; nuclear translocation to regulate stress-response genes; exercise-induced

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.